Burns J W & Co. Inc. NY reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,146 shares of the biopharmaceutical company’s stock after selling 5,085 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Gilead Sciences were worth $2,063,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares in the last quarter. Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. increased its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. acquired a new position in Gilead Sciences in the first quarter valued at $143,000. Hedge funds and other institutional investors own 74.05% of the company’s stock.
GILD has been the topic of a number of recent research reports. ValuEngine lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective on the stock. in a research note on Wednesday, June 21st. BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Leerink Swann restated a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Eleven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $83.79.
Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.09% during trading on Friday, hitting $82.36. 12,401,948 shares of the stock were exchanged. The stock’s 50-day moving average price is $77.16 and its 200-day moving average price is $70.20. The firm has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same period last year, the company posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/09/17/gilead-sciences-inc-gild-shares-sold-by-burns-j-w-co-inc-ny.html.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.